AstraZeneca has upped its revenue expectations following a strong second quarter, saying that sales of newer drugs will offset a major patent expiry and the impact of Brexit. Under the leadership ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback